Test: Infection, Tumor imaging, and Therapy Review Test (3/3) (employee training


Infection, Tumor imaging, and Therapy Review Test (3/3)Versión en línea Multiple choice por Joshua Liberty 1 Yttrium (90Y)-Ibritumomab tiuxetan 1rst step in therapy is? a Give IV rituximab, which is cold antibody; this blocks CD20 sites in peripheral circulation and RES uptake; pretreat with acetaminophen and diphenhydramine for fever/chills b Wait 7-9 days, then give 2nd infusion IV cold rituximab followed by therapeutic dose 0.3 or 0.4 mCi/kg (<32 mCi) Y-90 labeled Ibritumomab c Give 4 mCi/kg of Y-90 non-labeled rphx d Give 0.4 mCi/kg of Y-90 non-labeled rphx 2 Yttrium (90Y)-Ibritumomab tiuxetan 2nd step in therapy is? a Give IV rituximab, which is cold antibody; this blocks CD20 sites in peripheral circulation and RES uptake; pretreat with acetaminophen and diphenhydramine for fever/chills b Wait 7-9 days, then give 2nd infusion IV cold rituximab followed by therapeutic dose 0.3 or 0.4 mCi/kg (<32 mCi) Y-90 labeled Ibritumomab c Give 4 mCi/kg of Y-90 non-labeled rphx d Give 0.4 mCi/kg of Y-90 non-labeled rphx 3 Iobenguane I-131 Dosimetric (not therapy) dose is? a Patients weighing greater than 25 kg: 5 or 6 mCi, Patients weighing 50 kg or less: 0.9 mCi/kg b Patients weighing greater than 50 kg: 5 or 6 mCi, Patients weighing 50 kg or less: 1 mCi/kg c Patients weighing greater than 50 kg: 3 or 4 mCi, Patients weighing 50 kg or less: 0.1 mCi/kg d Patients weighing greater than 50 kg: 5 or 6 mCi, Patients weighing 50 kg or less: 0.1 mCi/kg 4 Iobenguane I-131 patient prep includes: patients should increase fluid intake to at least 2 L a day starting at least 1 day before and continuing for 1 week after each iobengaune I-131 dose _______? a To minimize irradiation to the bladder b To reduce bladder in FOV c To prevent vomiting d To increase the TNT ratio 5 Iobengaune I-131 Therapy dose is? a Patients weighing > than 92.5 kg: 500 mCi, Patients weighing 62.5 kg or <: 8 mCi/kg b Patients weighing > than 62.5 kg: 500 mCi, Patients weighing 62.5 kg or <: 8 mCi/kg c Patients weighing > than 62.5 kg: 600 mCi, Patients weighing 62.5 kg or <: 5 mCi/kg d Patients weighing > than 62.5 kg: 500 mCi, Patients weighing 62.5 kg or <: 4 mCi/kg 6 Fluciclovine F-18 dose is? a 5 mCi b 15-20 mCi c 6 mCi d 10 mCi 7 Fluciclovine F-18 MOL is? a Compartmental near prostate glandular tissue b Synthetic amino acid transported across mammalian cell membranes by amino acid transproters, such as LAT-1 and ASCT2, which are upregulated in neuroendocrine tumors c Synthetic amino acid transported across mammalian cell membranes by amino acid transproters, such as LAT-1 and ASCT2, which are upregulated in prostate cancer cells d Passive diffusion into prostate cancer cells 8 Lutetium Lu-177 dotatate MOL or mechanism of action is? a Passive diffusion through cell membrane of normal/malignant B lymphocytes b Synthetic amino acid transported across mammalian cell membranes by amino acid transproters, such as LAT-1 and ASCT2, which are upregulated in neuroendocrine tumors c Synthetic amino acid transported across mammalian cell membranes by amino acid transproters, such as LAT-1 and ASCT2, which are upregulated in prostate cancer cells d Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized 9 Fluciclovine F-18 patient prep includes? a Avoid any significant exercise for at least one day prior to PET imaging b No food or water 8 hours prior to injection c Block thyroid using inorganic iodine d Administer IV amino acid solution containing L-lysine and L-arginine 30 minutes before administering dose. Continue the infusion during, and for at least 3 hours after dose infusion. This is done for renal protection 10 Lutetium Lu-177 Dotatate recommended dose is? a 100 mCi every 8 weeks for a total of 4 doses b 200 mCi every 8 weeks for a total of 4 doses c 200 mCi every 4 weeks for a total of 4 doses d 200 mCi every 2 weeks for a total of 4 doses 11 Lutetium Lu-177 Dotatate patient prep includes? a Avoid any significant exercise for at least one day prior to PET imaging b No food or water 4 hours prior to injection c Block thyroid using inorganic iodine d Administer IV amino acid solution containing L-lysine and L-arginine 30 minutes before administering dose. Continue the infusion during, and for at least 3 hours after dose infusion. This is done for renal protection 12 Lutetium Lu-177 Dotatate causes? a Excessive bone irradiation b Known cardiac damage c Myelosuppression d Lung radiation pneumonitis if shunting occurs 13 Lu-177 Dotatate critical organ is? a Liver b Spleen c Kidneys d Bladder 14 Cu-64 dotatate dose is ? a 4 mCi b 15-20 mCi c 6 mCi d 10 mCi e 10-15 mCi 15 Piflufolastat F-18 dose is? a 4 mCi b 9 mCi (range 8-10 mCi) c 6 mCi d 0.4 mCi/kg e 10-15 mCi 16 The recommended start time for image acquisition is ___ minutes after Piflufolastat injection. Starting image acquisition more than ____ minutes after injection may adversely impact imaging performance. a 60; 90 b 30; 60 c 15; 30 d 90; 120 e 120;180 17 Cu-64 Tp is? a 6.6 days b 64 hours c 64 minutes d 12.7 hours e 12.7 days 18 Regarding Cu-64 dotatate patient prep, for patients on long-acting somatostatin analogs, a wash-out period of ____ is recommended prior to imaging. a 14 days; 2 days b 28 days; 2 days c 28 hours; 2 hours d 14 days; 7 days e 28 days; 4 days 19 Piflufolastat F-18 MOL or mechanism of action is? a Binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA b Synthetic amino acid transported across mammalian cell membranes by amino acid transporters, such as LAT-1 and ASCT2, which are upregulated in neuroendocrine tumors c Synthetic amino acid transported across mammalian cell membranes by amino acid transporters, such as LAT-1 and ASCT2, which are upregulated in prostate cancer cells d Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized 20 A patient is having Y90 Resin Microspheres therapy. He has >50% liver involvement, dose =? a 3 GBq b 5 GBq c 2.5 GBq d 2 GBq 21 Lymphoscintigraphy may use a CO-57 flood source; this is called a? a Flow image b Transmission scan c Emission scan d Blood pool scan 22 Ideal matrix size for a PET/CT scan would be ___ or higher a 512x512 b 32x32 c 128x128 d 64x64 23 A technologist draws an ROI too small on a lesion which takes up FDG. The result will be ? a Higher average SUV b Lower average SUV c No effect on SUV d No effect on SUV if AC was used 24 Melanoma tumor thickness is called the? a SUV b Clark index c Breslow index d Arelle index e Ritter index 25 A patient is on dextrose; it should be discontinued ______ before FDG injection. a 8-10 hours b 1-2 hours c 3-4 hours d 6-8 hours e 10-12 hours

1

Yttrium (90Y)-Ibritumomab tiuxetan 1rst step in therapy is?

a

Give IV rituximab, which is cold antibody; this blocks CD20 sites in peripheral circulation and RES uptake; pretreat with acetaminophen and diphenhydramine for fever/chills

b

Wait 7-9 days, then give 2nd infusion IV cold rituximab followed by therapeutic dose 0.3 or 0.4 mCi/kg (<32 mCi) Y-90 labeled Ibritumomab

c

Give 4 mCi/kg of Y-90 non-labeled rphx

d

Give 0.4 mCi/kg of Y-90 non-labeled rphx

2

Yttrium (90Y)-Ibritumomab tiuxetan 2nd step in therapy is?

a

Give IV rituximab, which is cold antibody; this blocks CD20 sites in peripheral circulation and RES uptake; pretreat with acetaminophen and diphenhydramine for fever/chills

b

Wait 7-9 days, then give 2nd infusion IV cold rituximab followed by therapeutic dose 0.3 or 0.4 mCi/kg (<32 mCi) Y-90 labeled Ibritumomab

c

Give 4 mCi/kg of Y-90 non-labeled rphx

d

Give 0.4 mCi/kg of Y-90 non-labeled rphx

3

Iobenguane I-131 Dosimetric (not therapy) dose is?

a

Patients weighing greater than 25 kg: 5 or 6 mCi, Patients weighing 50 kg or less: 0.9 mCi/kg

b

Patients weighing greater than 50 kg: 5 or 6 mCi, Patients weighing 50 kg or less: 1 mCi/kg

c

Patients weighing greater than 50 kg: 3 or 4 mCi, Patients weighing 50 kg or less: 0.1 mCi/kg

d

Patients weighing greater than 50 kg: 5 or 6 mCi, Patients weighing 50 kg or less: 0.1 mCi/kg

4

Iobenguane I-131 patient prep includes: patients should increase fluid intake to at least 2 L a day starting at least 1 day before and continuing for 1 week after each iobengaune I-131 dose _______?

a

To minimize irradiation to the bladder

b

To reduce bladder in FOV

c

To prevent vomiting

d

To increase the TNT ratio

5

Iobengaune I-131 Therapy dose is?

a

Patients weighing > than 92.5 kg: 500 mCi, Patients weighing 62.5 kg or <: 8 mCi/kg

b

Patients weighing > than 62.5 kg: 500 mCi, Patients weighing 62.5 kg or <: 8 mCi/kg

c

Patients weighing > than 62.5 kg: 600 mCi, Patients weighing 62.5 kg or <: 5 mCi/kg

d

Patients weighing > than 62.5 kg: 500 mCi, Patients weighing 62.5 kg or <: 4 mCi/kg

6

Fluciclovine F-18 dose is?

a

5 mCi

b

15-20 mCi

c

6 mCi

d

10 mCi

7

Fluciclovine F-18 MOL is?

a

Compartmental near prostate glandular tissue

b

Synthetic amino acid transported across mammalian cell membranes by amino acid transproters, such as LAT-1 and ASCT2, which are upregulated in neuroendocrine tumors

c

Synthetic amino acid transported across mammalian cell membranes by amino acid transproters, such as LAT-1 and ASCT2, which are upregulated in prostate cancer cells

d

Passive diffusion into prostate cancer cells

8

Lutetium Lu-177 dotatate MOL or mechanism of action is?

a

Passive diffusion through cell membrane of normal/malignant B lymphocytes

b

Synthetic amino acid transported across mammalian cell membranes by amino acid transproters, such as LAT-1 and ASCT2, which are upregulated in neuroendocrine tumors

c

Synthetic amino acid transported across mammalian cell membranes by amino acid transproters, such as LAT-1 and ASCT2, which are upregulated in prostate cancer cells

d

Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized

9

Fluciclovine F-18 patient prep includes?

a

Avoid any significant exercise for at least one day prior to PET imaging

b

No food or water 8 hours prior to injection

c

Block thyroid using inorganic iodine

d

Administer IV amino acid solution containing L-lysine and L-arginine 30 minutes before administering dose. Continue the infusion during, and for at least 3 hours after dose infusion. This is done for renal protection

10

Lutetium Lu-177 Dotatate recommended dose is?

a

100 mCi every 8 weeks for a total of 4 doses

b

200 mCi every 8 weeks for a total of 4 doses

c

200 mCi every 4 weeks for a total of 4 doses

d

200 mCi every 2 weeks for a total of 4 doses

11

Lutetium Lu-177 Dotatate patient prep includes?

a

Avoid any significant exercise for at least one day prior to PET imaging

b

No food or water 4 hours prior to injection

c

Block thyroid using inorganic iodine

d

Administer IV amino acid solution containing L-lysine and L-arginine 30 minutes before administering dose. Continue the infusion during, and for at least 3 hours after dose infusion. This is done for renal protection

12

Lutetium Lu-177 Dotatate causes?

a

Excessive bone irradiation

b

Known cardiac damage

c

Myelosuppression

d

Lung radiation pneumonitis if shunting occurs

a

Binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA

b

Synthetic amino acid transported across mammalian cell membranes by amino acid transporters, such as LAT-1 and ASCT2, which are upregulated in neuroendocrine tumors

c

Synthetic amino acid transported across mammalian cell membranes by amino acid transporters, such as LAT-1 and ASCT2, which are upregulated in prostate cancer cells

d

Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized

20

A patient is having Y90 Resin Microspheres therapy. He has >50% liver involvement, dose =?

a

3 GBq

b

5 GBq

c

2.5 GBq

d

2 GBq

21

Lymphoscintigraphy may use a CO-57 flood source; this is called a?

a

Flow image

b

Transmission scan

c

Emission scan

d

Blood pool scan

22

Ideal matrix size for a PET/CT scan would be ___ or higher

a

512x512

b

32x32

c

128x128

d

64x64

23

A technologist draws an ROI too small on a lesion which takes up FDG. The result will be ?

a

Higher average SUV

b

Lower average SUV

c

No effect on SUV

d

No effect on SUV if AC was used

24

Melanoma tumor thickness is called the?

a

SUV

b

Clark index

c

Breslow index

d

Arelle index

e

Ritter index

25

A patient is on dextrose; it should be discontinued ______ before FDG injection.

a

8-10 hours

b

1-2 hours

c

3-4 hours

d

6-8 hours

e

10-12 hours

Infection, Tumor imaging, and Therapy Review Test (3/3)

Test

Descarga la versión para jugar en papel

Creada por

Top 10 resultados

Top juegos

Test

Verbos irregulares en Inglés

Test

Tipos de sintagmas (II)

Test

cuanto sabes de Futbol

Test

Brawl stars preguntas

Test

Cultura general española